Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.
暂无分享,去创建一个
[1] William J Jusko,et al. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. , 2009, Drug metabolism and pharmacokinetics.
[2] T. Prueksaritanont,et al. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited , 2010, Biopharmaceutics & drug disposition.
[3] W Wang,et al. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.
[4] J. Reichert. Antibodies to watch in 2016 , 2016, mAbs.
[5] Irene van den Broek,et al. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[6] Meindert Danhof,et al. Systems pharmacology - Towards the modeling of network interactions. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[7] R. Kelley,et al. Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys , 2013, mAbs.
[8] D. Salinger,et al. Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies , 2011, Clinical pharmacokinetics.
[9] B. Ploeger,et al. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. , 2008, Trends in pharmacological sciences.
[10] M. Sliwkowski,et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose , 2012, Cancer Chemotherapy and Pharmacology.
[11] Denise M O'Hara,et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies , 2016, mAbs.
[12] Rene Bruno,et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.
[13] G Levy,et al. Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.
[14] F. Theil,et al. Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys , 2010, Drug Metabolism and Disposition.
[15] N. Benson,et al. The rise of systems pharmacology in drug discovery and development. , 2014, Future medicinal chemistry.
[16] F. Theil,et al. Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations , 2012, The AAPS Journal.
[17] M. Czuczman,et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Heather Myler,et al. Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.
[19] D. Shah,et al. Antibody biodistribution coefficients , 2013, mAbs.
[20] S. Akilesh,et al. FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.
[21] Zinnia P. Parra-Guillen,et al. Review on modeling anti-antibody responses to monoclonal antibodies , 2014, Journal of Pharmacokinetics and Pharmacodynamics.
[22] Saileta Prabhu,et al. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data , 2011, mAbs.
[23] Min Xu,et al. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A , 2016, mAbs.
[24] L. V. D. van de Putte,et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.
[25] K Gadkar,et al. A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.
[26] Kiran Mukhyala,et al. Effects of charge on antibody tissue distribution and pharmacokinetics. , 2010, Bioconjugate chemistry.
[27] Y. Yabe,et al. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. , 2011, Drug metabolism and pharmacokinetics.
[28] Paul Morgan,et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.
[29] M. P. Griffin,et al. A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults , 2013, Antimicrobial Agents and Chemotherapy.
[30] F. Theil,et al. Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans , 2012, Pharmaceutical Research.
[31] S. Iyer,et al. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[32] J. Treadway,et al. The Application of Target Information and Preclinical Pharmacokinetic/Pharmacodynamic Modeling in Predicting Clinical Doses of a Dickkopf-1 Antibody for Osteoporosis , 2010, Journal of Pharmacology and Experimental Therapeutics.
[33] Ken A. Dill,et al. In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability , 2014, Proceedings of the National Academy of Sciences.
[34] G. Proetzel,et al. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. , 2014, Methods.
[35] Y. Vugmeyster,et al. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. , 2012, World journal of biological chemistry.
[36] I. Sandlie,et al. Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding* , 2009, The Journal of Biological Chemistry.
[37] Andrew C. Chan,et al. Therapeutic antibodies for autoimmunity and inflammation , 2010, Nature Reviews Immunology.
[38] S. Tannenbaum,et al. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. , 2009, British journal of clinical pharmacology.
[39] F. Brennan,et al. Optimized Nonclinical Safety Assessment Strategies Supporting Clinical Development of Therapeutic Monoclonal Antibodies Targeting Inflammatory Diseases , 2014, Drug development research.
[40] B. Meibohm,et al. Population Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.
[41] John D. Davis,et al. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. , 2016, Biopharmaceutics & drug disposition.
[42] R. Ober,et al. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.
[43] Honghui Zhou,et al. Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look , 2009, Journal of clinical pharmacology.
[44] Jeanine L. Bussiere,et al. Species selection considerations for preclinical toxicology studies for biotherapeutics , 2008 .
[45] P. Vicini,et al. A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics , 2013, The AAPS Journal.
[46] S. Prabhu,et al. Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies , 2012, mAbs.
[47] M. Morris,et al. Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration , 2012, The AAPS Journal.
[48] Sean P. Lear,et al. Off-Target Platelet Activation in Macaques Unique to a Therapeutic Monoclonal Antibody , 2012, Toxicologic pathology.
[49] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[50] H. Kropshofer,et al. Immunogenicity: Its Impact on ADME of Therapeutic Biologics , 2015 .
[51] Michael M. Schmidt,et al. Factors determining antibody distribution in tumors. , 2008, Trends in pharmacological sciences.
[52] M. Dennis,et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4 , 2011, mAbs.
[53] E. Kraynov,et al. A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition , 2012, Journal of Pharmacology and Experimental Therapeutics.
[54] K Dane Wittrup,et al. Practical theoretic guidance for the design of tumor-targeting agents. , 2012, Methods in enzymology.
[55] J. Marvin,et al. Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates , 2009, The Journal of Immunology.
[56] W. Jusko,et al. Mechanistic Physiologically Based Pharmacokinetic Models in Development of Therapeutic Monoclonal Antibodies , 2015 .
[57] K. Haas,et al. The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy , 2004, The Journal of experimental medicine.
[58] Saileta Prabhu,et al. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? , 2012, Expert opinion on drug metabolism & toxicology.
[59] Y. Vugmeyster,et al. Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species , 2011, Pharmaceutical Research.
[60] Lisa J. Bernstein,et al. A strategy for risk mitigation of antibodies with fast clearance , 2012, mAbs.
[61] K. Gadkar,et al. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[62] J. Balthasar,et al. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy , 2014, Cancer biology & medicine.
[63] Y. Vugmeyster,et al. Challenges and Opportunities in Absorption, Distribution, Metabolism, and Excretion Studies of Therapeutic Biologics , 2012, The AAPS Journal.